Skip to content
2000
Volume 21, Issue 3
  • ISSN: 1573-3947
  • E-ISSN: 1875-6301

Abstract

Background

Worldwide, breast and endometrial carcinomas are the two most common cancers of women, but their coexistence in a woman <40 years of age is a rare event. The risk of developing a new second primary cancer is higher in cancer survivors compared to those without a history of cancer. The exact pathogenesis of two different primary malignancies is not clear. Still, the coexistence of breast and endometrial carcinoma may be due to germline mutations of p53, BRCA 1, and BRCA 2 genes, environmental, hereditary, and immune-mediated factors.

Case Presentation

The present case report briefs the finding of a 37-year-old woman who presented to the Gynecological outpatient department with complaints of abnormal uterine bleeding and a solid irregular lump in the upper outer quadrant of the right breast and the right axilla. She had a history of modified radical mastectomy for left breast ductal carcinoma five years back. She was diagnosed as a case of metachronous endometrial carcinoma (stage IA) with a recurrence of invasive ductal carcinoma in the right breast with metastasis to the right axillary lymph node.

Conclusion

The metachronous development of breast and endometrial carcinoma in young women is relatively rare. In young patients <40 years of age with gynecological or breast carcinoma, a thorough work-up, including genetic testing and follow-up, should be done for early diagnosis of metachronous or synchronous primary malignancies of other organs.

Loading

Article metrics loading...

/content/journals/cctr/10.2174/0115733947283731240215102133
2024-02-23
2025-09-04
Loading full text...

Full text loading...

References

  1. LeiS. ZhengR. ZhangS. WangS. ChenR. SunK. ZengH. ZhouJ. WeiW. Global patterns of breast cancer incidence and mortality: A population‐based cancer registry data analysis from 2000 to 2020.Cancer Commun.202141111183119410.1002/cac2.1220734399040
    [Google Scholar]
  2. Cancer Stat FactsUterine Cancer. National Cancer Institute. Surveillance, Epidemiology, and End Results Program.Available from: https://seer.cancer.gov/statfacts/html/corp.html
  3. BanimostafaviE.S. TayebiS. TayebiM. MontazerF. Case Report: Synchronous primary malignancy including the breast and endometrium.F1000 Res.20176150210.12688/f1000research.11971.129333235
    [Google Scholar]
  4. ChoiS. LeeY.J. JeongJ.H. JungJ. LeeJ.W. KimH.J. KoB.S. SonB.H. AhnS.H. LeeY. ChungI.Y. Risk of endometrial cancer and frequencies of invasive endometrial procedures in young breast cancer survivors treated with tamoxifen: A nationwide study.Front. Oncol.20211163637810.3389/fonc.2021.63637834150613
    [Google Scholar]
  5. SunC. ChenG. YangZ. JiangJ. YangX. LiN. ZhouB. ZhuT. WeiJ. WengD. MaD. WangC. KongB. Safety of ovarian preservation in young patients with early-stage endometrial cancer: A retrospective study and meta-analysis.Fertil. Steril.20131003782787.e510.1016/j.fertnstert.2013.05.03223830105
    [Google Scholar]
  6. SateiJ. AfrakhtehA.N. AldecoaK.A.T. Endometrial adenocarcinoma in young women: A case report and review of literature.Cureus2023159e4528710.7759/cureus.4528737846282
    [Google Scholar]
  7. BrintonL.A. ShermanM.E. CarreonJ.D. AndersonW.F. Recent trends in breast cancer among younger women in the United States.J. Natl. Cancer Inst.2008100221643164810.1093/jnci/djn34419001605
    [Google Scholar]
  8. ErićI. Petek ErićA. KristekJ. KoprivčićI. BabićM. Breast cancer in young women: Pathologic and immunohistochemical features.Acta Clin. Croat.201857349750210.20471/acc.2018.57.03.1331168183
    [Google Scholar]
  9. CollinsL.C. MarottiJ.D. GelberS. ColeK. RuddyK. KereakoglowS. BrachtelE.F. SchapiraL. ComeS.E. WinerE.P. PartridgeA.H. Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer.Breast Cancer Res. Treat.201213131061106610.1007/s10549‑011‑1872‑922080245
    [Google Scholar]
  10. LeeH.B. HanW. Unique features of young age breast cancer and its management.J. Breast Cancer201417430130710.4048/jbc.2014.17.4.30125548576
    [Google Scholar]
  11. GrzankowskiK.S. SzenderJ.B. Spring-RobinsonC.L. LeleS.B. OdunsiK.O. FrederickP.J. Evaluation of metachronous breast and endometrial cancers: Preroutine and postroutine adjuvant tamoxifen use.Int. J. Gynecol. Cancer20162681440144710.1097/IGC.000000000000078527648713
    [Google Scholar]
  12. Martin-DunlapT.M. WachtelM.S. MargenthalerJ.A. Outcomes for patients who are diagnosed with breast and endometrial cancer.Oncol. Lett.2013641103110710.3892/ol.2013.149124137471
    [Google Scholar]
  13. DerwingerK. GustavssonB. A study of aspects on gender and prognosis in synchronous colorectal cancer.Clin. Med. Insights Oncol.20115CMO.S787110.4137/CMO.S787121912492
    [Google Scholar]
  14. AydinerA. KaradenizA. UygunK. TasS. TasF. DisciR. TopuzE. Multiple primary neoplasms at a single institution: Differences between synchronous and metachronous neoplasms.Am. J. Clin. Oncol.200023436437010.1097/00000421‑200008000‑0001110955865
    [Google Scholar]
  15. PanS.Y. HuangC.P. ChenW.C. Synchronous/metachronous multiple primary malignancies: Review of associated risk factors.Diagnostics2022128194010.3390/diagnostics1208194036010291
    [Google Scholar]
  16. TzirisN. DokmetzioglouJ. GiannoulisK. KesisoglouI. SapalidisK. KotidisE. GambrosO. Synchronous and metachronous adenocarcinomas of the large intestine.Hippokratia200812315015218923668
    [Google Scholar]
  17. TravisL.B. HillD. DoresG.M. GospodarowiczM. van LeeuwenF.E. HolowatyE. GlimeliusB. AnderssonM. PukkalaE. LynchC.F. PeeD. SmithS.A. Van’t VeerM.B. JoensuuT. StormH. StovallM. BoiceJ.D.Jr GilbertE. GailM.H. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma.J. Natl. Cancer Inst.200597191428143710.1093/jnci/dji29016204692
    [Google Scholar]
  18. LaxS.F. Molecular genetic pathways in various types of endometrial carcinoma: From a phenotypical to a molecular-based classification.Virchows Arch.2004444321322310.1007/s00428‑003‑0947‑314747944
    [Google Scholar]
  19. FerrissJ.S. EricksonB.K. ShihI.M. FaderA.N. Uterine serous carcinoma: Key advances and novel treatment approaches.Int. J. Gynecol. Cancer20213181165117410.1136/ijgc‑2021‑00275334210768
    [Google Scholar]
  20. LiG. YaoJ. WuT. ChenY. WangZ. WangY. WangF. ZhongR. YangS. Triple metachronous primary cancer of uterus, colon, and breast cancer.Medicine20209934e2176410.1097/MD.000000000002176432846803
    [Google Scholar]
  21. AlamM. PerweenR. SiddiquiS. Triple malignancy involving breast, ovary, and uterine vault: A case report and literature review.J. Cancer Res. Ther.20171361059106110.4103/0973‑1482.22041929237978
    [Google Scholar]
  22. LeeE. JiY.I. A case of uterine carcinosarcoma detected simultaneously with breast and colon cancer (triple primary malignant tumor).Case Rep. Oncol.201811243143510.1159/00048984430057538
    [Google Scholar]
  23. VogtA. SchmidS. HeinimannK. FrickH. HerrmannC. CernyT. OmlinA. Multiple primary tumours: Challenges and approaches, a review.ESMO Open201722e00017210.1136/esmoopen‑2017‑00017228761745
    [Google Scholar]
  24. MooT.A. SanfordR. DangC. MorrowM. Overview of breast cancer therapy.PET Clin.201813333935410.1016/j.cpet.2018.02.00630100074
    [Google Scholar]
  25. PDQ Adult Treatment Editorial BoardEndometrial Cancer Treatment (PDQ®): Health Professional Version. 2023 Mar 13. In: PDQ cancer information summaries [Internet]. Bethesda (MD): National cancer institute.2002Available from: https://www.ncbi.nlm.nih.gov/books/NBK65829/
/content/journals/cctr/10.2174/0115733947283731240215102133
Loading
/content/journals/cctr/10.2174/0115733947283731240215102133
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test